The DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.
Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the Surveillance, Epidemiology, and End Results Program
Open accessAbstract
BACKGROUND: Osteosarcoma, which is the most common primary bone tumor, occurs most frequently in adolescents, but there is a second incidence peak among individuals aged >60 years. Most osteosarcoma epidemiology studies have been embedded in large analyses of all bone tumors or focused on cases occurring in adolescence. Detailed descriptions of osteosarcoma incidence and survival with direct comparisons among patients of all ages and ethnicities are not available. METHODS: Frequency, incidence, and survival rates for 3482 patients with osteosarcoma from the National Cancer Institute's population‐based Surveillance, Epidemiology, and End Results (SEER) Program between 1973 and 2004 were investigated by age (ages 0‐24 years, 25‐59 years, and 60 to ≥85 years), race, sex, pathology subtype, stage, and anatomic site. RESULTS: There were large differences in incidence and survival rates by age. There was a high percentage of osteosarcoma with Paget disease and osteosarcoma as a second or later cancer among the elderly. There was a high percentage of osteosarcoma among patients with Paget disease and osteosarcoma as a second or later cancer among the elderly. Tumor site differences among age groups were noted. Survival rates varied by anatomic site and disease stage and did not improve significantly from 1984 to 2004. CONCLUSIONS: This comprehensive, population‐based description of osteosarcoma, identified important differences in incidence, survival, pathologic subtype, and anatomic site among age groups, and quantified the impact of osteosarcoma in patients with Paget disease or as a second cancer on incidence and mortality rates. These findings may have implications in understanding osteosarcoma biology and epidemiology. Cancer 2009. © 2009 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Osteosarcoma is the most common primary malignant tumour of the bone.”
From Osteosarcoma (2022) · cites this paper as [1]
In the citing paper
“higher rates of osteosarcoma have been observed in African American children and young adults in the USA than in white individuals 1 .”
From Osteosarcoma (2022) · cites this paper as [1]
In the citing paper
“Osteosarcoma incidence is bimodal, peaking at 18 and 60 years of age”
From Osteosarcoma (2022) · cites this paper as [1]
In the citing paper
“Osteosarcoma incidence has a bimodal age distribution with a primary peak in adolescents and young adults and a second, smaller peak in the seventh and eighth decade of life 1”
From Osteosarcoma (2022) · cites this paper as [1]
In the citing paper
“In the USA, osteosarcoma accounts for <1% of all new cancer diagnoses with ~1,000 new cases diagnosed per year, half of these cases occurring in children and adolescents 1 .”
From Osteosarcoma (2022) · cites this paper as [1]
In the citing paper
“Some studies suggested that the histological subtype of osteosarcoma can influence the degree of necrosis, with chondroblastic and telangiectatic subtypes having less necrosis but those differences have not translated into improvement in survival 1,118 .”
From Osteosarcoma (2022) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
World Health Organization Classification of Tumours
Fletcher, C., van den Berg, A., & Molenaar, I. (2002) · Cited by 7,079
International Classification of Diseases for Oncology
National Cancer Institute (2020) · Definitions · doi:10.32388/1bjeus · Cited by 3,810
Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995
(1999) · PsycEXTRA Dataset · doi:10.1037/e407432005-001 · Cited by 1,933
The international incidence of childhood cancer
Parkin, D. M., Stiller, C. A., Draper, G. J., & Bieber, C. A. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910420408 · Cited by 1,022
Trends in childhood cancer incidence in the U.S. (1992–2004)
Linabery, A. M., & Ross, J. A. (2007) · Cancer · doi:10.1002/cncr.23169 · Cited by 644
Bleyer, A., O’Leary, M., Barr, R. D., & Ries, L. A. G. (2006) · Cited by 619
Osteosarcoma, Chondrosarcoma, and Ewing's Sarcoma
Damron, T. A., Ward, W. G., & Stewart, A. K. (2007) · Clinical Orthopaedics and Related Research · doi:10.1097/blo.0b013e318059b8c9 · Cited by 530
Osteogenic sarcoma. A study of six hundred cases.
Dahlin, D. C., & Coventry, M. B. (1967) · PubMed · Cited by 475
Bone Tumors: General Aspects and Data on 8,542 Cases
Spjut, H. J. (1987) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)61914-4 · Cited by 455
Dahlin, D. C., & Coventry, M. B. (1967) · Journal of Bone and Joint Surgery · doi:10.2106/00004623-196749010-00008 · Cited by 453
Flagged first, then by citations
2 of the 52 references couldn’t be matched to a known paper.
Research works printed but not linked: 12
- 10.1002/1097-0142(19950101)75:1 <203::AID-CNCR2820751308>3.0.CO;2-V · DOI
- Dorfman HA, 1997, Bone Tumors
- Murray RO, 1975, A Textbook of Radiology, 109
- Hanson MR, 1982, Epidemiology of Cancer in the Young
- 10.1002/1097-0142(19860715)58:2 <598::AID-CNCR2820581332>3.0.CO;2-C · DOI
- Surveillance, Epidemiology, and End Results Program of the National Cancer Institute, 2007, SEER Registries: Surveillance Research Program, National Cancer Institute
- Surveillance Research Program, 2007, National Cancer Institute SEER*Stat Software, version 6.3.6
- Day JC, 1996, Population Projections of the United States by Age, Sex, Race and Hispanic Origin, 1995 to 2050, US Bureau of the Census, Current Population Reports, P25‐1130
- Surveillance, Epidemiology, and End Results (SEER) Program, 2007, SEER*Stat Database: Incidence‐SEER 13 Regs Limited‐Use, November 2006 Submission (1992‐2004)‐Linked to County Attributes‐Total US, 1969‐2004 Counties
- Surveillance, Epidemiology, and End Results (SEER) Program, 2007, SEER*Stat Database: Incidence‐SEER 9 Regs Limited‐Use, November 2006 Submission (1973‐2004)‐Linked to County Attributes‐Total US, 1969‐2004 Counties
- Surveillance, Epidemiology, and End Results (SEER) Program, 2007, SEER*Stat Database: Incidence‐SEER 17 Regs Limited‐Use, November 2006 Submission (1973‐2004 varying)‐Linked to County Attributes‐Total US, 1969‐2004 Counties
- Aegerter E, 1975, Orthopedic Disease
Cited by
Sorted by citations
Items 501–600 of 1,002
PLA2G16 promotes osteosarcoma metastasis and drug resistance via the MAPK pathway
Li, L., Liang, S., Wasylishen, A. R., Zhang, Y., Yang, X., Zhou, B., Shan, L., Han, X., Mu, T., Wang, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7694 · Cited by 35
Canine osteosarcoma in comparative oncology: Molecular mechanisms through to treatment discovery
Simpson, S., Rizvanov, A. A., Jeyapalan, J. N., de Brot, S., & Rutland, C. S. (2022) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.965391 · Cited by 38
Autophagy and its role in osteosarcoma
Ning, B., Liu, Y., Huang, T., & Wei, Y. (2023) · Cancer Medicine · doi:10.1002/cam4.5407 · Cited by 36
Yang, J., Lou, S., & Yao, T. (2024) · Journal of bone oncology · doi:10.1016/j.jbo.2024.100607 · Cited by 34
miR-23a impairs bone differentiation in osteosarcoma via down-regulation of GJA1
Gindin, Y., Jiang, Y., Francis, P., Walker, R. L., Abaan, O. D., Zhu, Y. J., & Meltzer, P. S. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00233 · Cited by 34
miR-217 targeting Wnt5a in osteosarcoma functions as a potential tumor suppressor
Wei, R., Deng, Z., & Su, J. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.04.012 · Cited by 34
Surgical Treatment of Sarcomas of the Spine
Ozturk, A. K., Gokaslan, Z. L., & Wolinsky, J. (2014) · Current Treatment Options in Oncology · doi:10.1007/s11864-014-0290-8 · Cited by 34
Li, Z., Li, Y., Wang, N., Yang, L., Zhao, W., & Zeng, X. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.02.050 · Cited by 34
LI, X., YANG, H., Tian, Q., LIU, Y., & WENG, Y. (2014) · Neoplasma · doi:10.4149/neo_2014_056 · Cited by 34
MicroRNA-603 functions as an oncogene by suppressing BRCC2 protein translation in osteosarcoma
Ma, C., Zhan, C., Yuan, H., Cui, Y., & Zhang, Z. (2016) · Oncology Reports · doi:10.3892/or.2016.4718 · Cited by 35
Song, M., Wang, Y., Zhang, Z., & Wang, S. (2016) · Oncotarget · doi:10.18632/oncotarget.13511 · Cited by 34
Ma, B., Zhu, J., Zhao, A., Zhang, J., Wang, Y., Zhang, H., Zhang, L., & Zhang, Q. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.05.025 · Cited by 34
Zhang, Y., Zhang, Q., Xin, W., Liu, N., & Zhang, H. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s180610 · Cited by 34
Tumor Suppressor Function of miR-127-3p and miR-376a-3p in Osteosarcoma Cells
Fellenberg, J., Lehner, B., Sähr, H., Schenker, A., & Kunz, P. (2019) · Cancers · doi:10.3390/cancers11122019 · Cited by 34
Huang, H., Han, Y., Chen, Z., Pan, X., Yuan, P., Zhao, X., Zhu, H., Wang, J., Sun, X., & Shi, P. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15226 · Cited by 34
Wang, B., & Li, J. (2020) · Cancer Management and Research · doi:10.2147/cmar.s238173 · Cited by 34
Mishra, R., Nathani, S., Varshney, R., Sircar, D., & Roy, P. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05892-8 · Cited by 34
MYC amplifications are common events in childhood osteosarcoma
Noon, S. D., Ijaz, J., Coorens, T. H. H., Amary, F. M., Ye, H., Strobl, A., Lyskjær, I., Flanagan, A. M., & Behjati, S. (2021) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.219 · Cited by 34
Cardiovascular involvement by osteosarcoma: an analysis of 20 patients
Yedururi, S., Morani, A. C., Gladish, G. W., Vallabhaneni, S., Anderson, P. M., Hughes, D. P. M., Wang, W., & Daw, N. C. (2015) · Pediatric Radiology · doi:10.1007/s00247-015-3449-y · Cited by 34
The Prognostic Value of Serum Biomarkers in Localized Bone Sarcoma
Pedersen, N. A., Maretty‐Kongstad, K., Keller, J. O., Bærentzen, S., & Safwat, A. (2016) · Translational Oncology · doi:10.1016/j.tranon.2016.05.006 · Cited by 34
Hill, K. E., Kelly, A. D., Kuijjer, M. L., Barry, W. T., Rattani, A., Garbutt, C. C., Kissick, H. T., Janeway, K. A., Pérez‐Atayde, A. R., Goldsmith, J. D., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0465-4 · Cited by 34
Paludo, J., Fritchie, K., Haddox, C. L., Rose, P. S., Arndt, C. A. S., Marks, R. S., Galanis, E., Okuno, S. H., & Robinson, S. I. (2017) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000397 · Cited by 34
Chlorogenic acid inhibits osteosarcoma carcinogenesis via suppressing the STAT3/Snail pathway
Zhang, F., Yin, G., Han, X., Jiang, X.-Q., & Bao, Z. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28318 · Cited by 34
Wu, Z.-J., Tan, J.-C., Qin, X., Liu, B., & Yuan, Z.-C. (2018) · Cancer Management and Research · doi:10.2147/cmar.s176515 · Cited by 33
Tippett, V. L., Tattersall, L., Latif, N. A., Shah, K. M., Lawson, M. A., & Gartland, A. (2022) · Oncogene · doi:10.1038/s41388-022-02529-x · Cited by 33
Patkar, S., Mannheimer, J., Harmon, S. A., Ramirez, C. J., Mazcko, C. N., Choyke, P. L., Brown, G. T., Türkbey, B., LeBlanc, A. K., & Beck, J. A. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1854 · Cited by 35
Bone Morphogenetic Protein 9 Overexpression Reduces Osteosarcoma Cell Migration and Invasion
Lv, Z., Yang, D., Li, J., Hu, M., Luo, M., Zhan, X., Song, P., Liu, C., Bai, H., Li, B., et al. (2013) · Molecules and Cells · doi:10.1007/s10059-013-0043-8 · Cited by 33
Silencing of Barkor/ATG14 sensitizes osteosarcoma cells to cisplatin-induced apoptosis
Zhao, Z., Tao, L.-J., Shen, C., Liu, B., Yang, Z., & Tao, H. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1578 · Cited by 33
Follow-up practices for high-grade extremity Osteosarcoma
Rothermundt, C. A., Seddon, B. M., Dileo, P., Strauss, S. J., Coleman, J., Briggs, T. W. R., Haile, S. R., & Whelan, J. S. (2016) · BMC Cancer · doi:10.1186/s12885-016-2333-y · Cited by 33
Cisplatin promotes mesenchymal-like characteristics in osteosarcoma through Snail
Fang, S., Yu, L., Mei, H., Yang, J., Gao, T., Cheng, A.-Y., Guo, W., Xia, K., & Liu, G. (2016) · Oncology Letters · doi:10.3892/ol.2016.5342 · Cited by 33
Association of anti-HER2 antibody with graphene oxide for curative treatment of osteosarcoma
Li, L., Luo, C., Song, Z., Reyes‐Vargas, E., Clayton, F., Huang, J., Jensen, P. E., & Chen, X. (2017) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.11.001 · Cited by 33
Sugiyama, H., Omonishi, K., Yonehara, S., Ozasa, K., Kajihara, H., Tsuya, T., & Takeshima, Y. (2018) · JBJS Open Access · doi:10.2106/jbjs.oa.17.00064 · Cited by 33
TGM2 knockdown reverses cisplatin chemoresistance in osteosarcoma
Li, C., Cai, J., Fu-gui, G., & Wang, G. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3753 · Cited by 33
Overexpression of Notch3 is associated with metastasis and poor prognosis in osteosarcoma patients
Tang, X., Cao, Y., Peng, D.-B., Zhao, G., Zeng, Y., Gao, Z., Lv, Y., & Guo, Q. (2019) · Cancer Management and Research · doi:10.2147/cmar.s185495 · Cited by 33
TIM‑3 expression and its association with overall survival in primary osteosarcoma
Pu, F., Chen, F., Zhang, Z., Qing, X., Lin, H., Zhao, L., Xia, P., & Shao, Z. (2019) · Oncology Letters · doi:10.3892/ol.2019.10855 · Cited by 33
Potential diagnostic value of miRNAs in peripheral blood for osteosarcoma: A meta-analysis
Gao, S., Wang, Y., Zhang, G., & Zhang, W. (2020) · Journal of bone oncology · doi:10.1016/j.jbo.2020.100307 · Cited by 33
Lv, M., Xu, Q., Zhang, B., Yang, Z., Xie, J., Guo, J., He, F., & Wang, W. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02397-7 · Cited by 34
Dong, L., & Qu, F. (2020) · Journal of Molecular Histology · doi:10.1007/s10735-020-09883-8 · Cited by 33
Zhao, Q., Wang, C., Zhu, J., Wang, L., Dong, S.-H., Zhang, G., & Tian, J. (2011) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-30-26 · Cited by 33
Clinical and radiographic presentation of pelvic sarcoma in children
Kadhim, M. B., Oyoun, N. A., Womer, R. B., & Dormans, J. P. (2018) · SICOT-J · doi:10.1051/sicotj/2018040 · Cited by 32
Lu, Y., Liu, A., Jin, S., Dai, J., Yu, Y., Wen, P., Zheng, Y., & Xia, D. (2024) · Advanced Materials · doi:10.1002/adma.202410589 · Cited by 32
Li, W., He, X., Xue, R., Zhang, Y., Zhang, X., Lu, J., Zhang, Z., & Li, X. (2016) · Pathology - Research and Practice · doi:10.1016/j.prp.2016.06.013 · Cited by 32
Slit-Robo GTPase-Activating Protein 2 as a metastasis suppressor in osteosarcoma
Marko, T. A., Shamsan, G. A., Edwards, E. N., Hazelton, P. E., Rathe, S. K., Cornax, I., Overn, P., Varshney, J., Diessner, B. J., Moriarity, B. S., et al. (2016) · Scientific Reports · doi:10.1038/srep39059 · Cited by 32
Wang, H., Yu, Y., Fan, S., & Luo, L. (2017) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504017x14908298412505 · Cited by 32
RetractedSun, Z., Li, A., Yu, Z., Li, X., Guo, X., & Chen, R. (2017) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2017.2268 · Cited by 32
On the biomechanical properties of osteosarcoma cells and their environment
Müller, D. A., & Silván, U. (2019) · The International Journal of Developmental Biology · doi:10.1387/ijdb.190019us · Cited by 32
Zhong, B., Shi, D., Wu, F., Wang, S., Hu, H., Cheng, C., Qing, X., Huang, X., Luo, X., Zhang, Z., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1917-2 · Cited by 32
Metabolism of Reactive Oxygen Species in Osteosarcoma and Potential Treatment Applications
Sun, W., Wang, B., Qu, X., Zheng, B., Huang, W., Sun, Z., Wang, C., & Chen, Y. (2019) · Cells · doi:10.3390/cells9010087 · Cited by 32
Wei, W., Ji, L., Duan, W., & Zhu, J. (2021) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-020-02169-5 · Cited by 32
Hu, X., Deng, K., Ye, H., Sun, Z., Huang, W., Sun, Y., & Yan, W. (2021) · Cancers · doi:10.3390/cancers13215381 · Cited by 34
Tumor-Suppressing Effects of miR-141 in Human Osteosarcoma
Xu, H., Mei, Q., Xiong, C., & Zhao, J. (2013) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-013-9801-7 · Cited by 32
ZBTB7C m6A modification incurred by METTL3 aberration promotes osteosarcoma progression
An, X., Wu, W., Yang, L., Dong, J., Liu, B., Guo, J., Chen, J., Guo, B., Cao, W., & Jiang, Q. Y. (2023) · Translational research · doi:10.1016/j.trsl.2023.04.005 · Cited by 32
Liu, B., Lu, Y., Li, J., Liu, Y., Liu, J., & Wang, W. (2015) · Apmis · doi:10.1111/apm.12427 · Cited by 32
Guillon, M., Mary, P., Brugière, L., Marec‐Bérard, P., Pacquement, H., Schmitt, C., Guinebretière, J., & Tabone, M. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-407 · Cited by 32
Yang, F., Nam, S., Zhao, R., Tian, Y., Liu, L., Horne, D. A., & Jove, R. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.26045 · Cited by 32
Liu, S., Deng, S., He, Y., & Ni, G. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.11.145 · Cited by 32
MicroRNA-192-5p suppresses the initiation and progression of osteosarcoma by targeting USP1
Zhou, S., Xiong, M., Dai, G., Yu, L., Zhang, Z., Chen, J., & Guo, W. (2018) · Oncology Letters · doi:10.3892/ol.2018.8180 · Cited by 32
Genetically transforming human osteoblasts to sarcoma: development of an osteosarcoma model
Yang, Y., Yang, R. R., Roth, M. E., Piperdi, S., Zhang, W., Dorfman, H. D., Rao, P. H., Park, A., Tripathi, S., Freeman, C., et al. (2017) · Genes & Cancer · doi:10.18632/genesandcancer.133 · Cited by 32
Wang, Z., Wen, P., Luo, X., Fang, X., Wang, Q., Ma, F., & Lv, J. (2013) · Tumor Biology · doi:10.1007/s13277-013-1475-7 · Cited by 31
Association of RECQL5 gene polymorphisms and osteosarcoma in a Chinese Han population
Zhi, L., Ma, W., Zhang, H., Zeng, S., & Chen, B. (2013) · Tumor Biology · doi:10.1007/s13277-013-1425-4 · Cited by 31
MicroRNA-181a promotes proliferation and inhibits apoptosis by suppressing CFIm25 in osteosarcoma
Zhu, Z.-J., Huang, P., Chong, Y., Kang, L., Huang, X., Zhu, Z.-X., & Nie, L. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5741 · Cited by 31
A novel prognostic model for osteosarcoma using circulating CXCL 10 and FLT 3 LG
Flores, R. J., Kelly, A. J., Li, Y., Nakka, M., Barkauskas, D. A., Krailo, M., Wang, L. L., Perlaky, L., Lau, C. C., Hicks, J. M., et al. (2016) · Cancer · doi:10.1002/cncr.30272 · Cited by 31
Zhou, Y., Han, Y., Zhang, Z., Shi, Z., Zhou, L., Liu, X., & Jia, X. (2016) · Human Cell · doi:10.1007/s13577-016-0148-4 · Cited by 31
He, Y., Zhu, W., Shin, M. H., Gary, J. M., Liu, C., Dubois, W., Hoover, S. B., Jiang, S., Marrogi, E., Mock, B. A., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.04.029 · Cited by 31
LncRNA expression and implication in osteosarcoma: a systematic review and meta-analysis
Wang, Y., Huang, Y., Xiang, P., & Tian, W. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s149889 · Cited by 31
Ma, L., Zhang, L., Guo, A., Liu, L., Yu, F., Diao, N., Xu, C., & Wang, D. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.04.004 · Cited by 31
Liu, G. (2025) · American Journal of Translational Research · doi:10.62347/jvrm8589 · Cited by 31
RetractedApplication of additively manufactured 3D scaffolds for bone cancer treatment: a review
Hou, Y., Wang, W., & Bártolo, P. (2022) · Bio-Design and Manufacturing · doi:10.1007/s42242-022-00182-7 · Cited by 31
Kaneuchi, Y., Yoshida, S., Fujiwara, T., Evans, S., & Abudu, A. (2022) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2022.04.001 · Cited by 31
Dong, Y., Xu, T.-Y., Fan, L., Liu, K., & Li, G. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01670-3 · Cited by 31
Wang, M., Xu, N.-Y., Tang, R.-Z., & Liu, X. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100295 · Cited by 31
Yuan, H., & Gao, Y. (2015) · Oncology Reports · doi:10.3892/or.2015.4242 · Cited by 31
Mohseny, A. B., Xiao, W., Carvalho, R., Spaink, H. P., Hogendoorn, P. C. W., & Cleton-Jansen, A. (2012) · The Journal of Pathology · doi:10.1002/path.3998 · Cited by 31
Knockdown of Akt Sensitizes Osteosarcoma Cells to Apoptosis Induced by Cisplatin Treatment
Zhang, G., Li, M., Zhu, X., Bai, Y., & Yang, C. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12052994 · Cited by 31
hTERT promoter activity identifies osteosarcoma cells with increased EMT characteristics
Yu, L., Liu, S., Guo, W., Zhang, C., Zhang, B., Yan, H., & Wu, Z. (2013) · Oncology Letters · doi:10.3892/ol.2013.1692 · Cited by 31
Prognostic role of hypoxia-inducible factor-1 alpha expression in osteosarcoma: a meta-analysis
Ren, H., Li, H., Xie, T., Sun, L., Zhu, T., Wang, S. D., Ye, Z. M., & Zhang, Y. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s95490 · Cited by 31
Cheng, Z.-X., Guo, Y., Yang, Y., Kan, J., Dai, S., Helian, M., Li, B., Xu, J., & Liu, C. (2016) · Oncology Reports · doi:10.3892/or.2016.4846 · Cited by 31
AICAR induces mitochondrial apoptosis in human osteosarcoma cells through an AMPK-dependent pathway
Morishita, M., Kawamoto, T., Hara, H., Onishi, Y., Ueha, T., Minoda, M., Katayama, E., Takemori, T., Fukase, N., Kurosaka, M., et al. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3775 · Cited by 31
Comparative oncology approach to drug repurposing in osteosarcoma
Parrales, A., McDonald, P. R., Ottomeyer, M., Roy, A., Shoenen, F. J., Broward, M. A., Bruns, T., Thamm, D. H., Weir, S. J., Neville, K. A., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194224 · Cited by 31
Qiao, B., Shui, W., Cai, L., Guo, S., & Jiang, D. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s77116 · Cited by 30
Liang, H., Cui, M., Tu, J., & Chen, X. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1394339 · Cited by 30
Zhao, W., You, C., Zhuang, J., Zu, J., Chi, Z., Xu, G., & Yan, J. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1740-5 · Cited by 30
Genetic Factors Conferring Metastasis In Osteosarcoma
Maximov, V. V., & Aqeilan, R. I. (2016) · Future Oncology · doi:10.2217/fon-2016-0014 · Cited by 30
A Validated Preclinical Animal Model for Primary Bone Tumor Research
Wagner, F., Holzapfel, B. M., Thibaudeau, L., Straub, M., Ling, M., Grifka, J. K., Loessner, D., Lévesque, J.-P., & Hutmacher, D. W. (2016) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.15.00920 · Cited by 31
Oncolytic adenoviruses as a therapeutic approach for osteosarcoma: A new hope
García-Moure, M., Martínez-Vélez, N., Patiño‐García, A., & Alonso, M. M. (2016) · Journal of bone oncology · doi:10.1016/j.jbo.2016.12.001 · Cited by 30
Zeng, S., Cai, Q.-C., Guo, C.-H., Zhi, L., Dai, X., Zhang, D., & Ma, W. (2017) · Oncology Reports · doi:10.3892/or.2017.5842 · Cited by 30
miR‑491‑5p inhibits osteosarcoma cell proliferation by targeting PKM2
Chen, T., Li, Y., Cao, W., & Liu, Y. (2018) · Oncology Letters · doi:10.3892/ol.2018.9451 · Cited by 30
Overexpression of miR-1258 inhibits cell proliferation by targeting AKT3 in osteosarcoma
Liu, W., Zhou, Z., Zhang, Q., Rong, Y., Li, L., Luo, Y., Wang, J., Yin, G., Lv, C., & Cai, W. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.01.139 · Cited by 30
Song, H.-J., Jiao, Y., Wei, W., Ren, X., Shen, C., Qiu, Z., Yang, Q., Wang, Q., & Luo, Q. (2019) · European Radiology · doi:10.1007/s00330-019-06074-2 · Cited by 30
Liu, W. (2019) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2018.2684 · Cited by 30
Knocking down miR-384 promotes growth and metastasis of osteosarcoma MG63 cells by targeting SLBP
Wang, Y., Huang, H., & Li, Y. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1601099 · Cited by 30
CYR61 triggers osteosarcoma metastatic spreading via an IGF1Rβ-dependent EMT-like process
Habel, N., Stefanovska, B., Carène, D., Patiño‐García, A., Lecanda, F., & Fromigué, O. (2019) · BMC Cancer · doi:10.1186/s12885-019-5282-4 · Cited by 30
Moradi, M., Abdolhosseini, M., Zarrabi, A., & Johari, B. (2019) · Nano-Structures & Nano-Objects · doi:10.1016/j.nanoso.2019.100348 · Cited by 30
Pan, Y., Chen, D., Hu, T., Lv, G., & Dai, Z. (2019) · Cancer Control · doi:10.1177/1073274819888893 · Cited by 30
miR-1225-5p Functions as a Tumor Suppressor in Osteosarcoma by Targeting Sox9
Zhang, W., Wei, L., Sheng, W., Kang, B., Wang, D., & Zeng, H. (2019) · DNA and Cell Biology · doi:10.1089/dna.2019.5105 · Cited by 30
Wang, L. (2020) · Journal of bone oncology · doi:10.1016/j.jbo.2020.100335 · Cited by 30
Zhang, W., Zhao, W., Li, Q., Zhao, D., Qu, J., Yuan, Z., Cheng, Z., Zhu, X., Zhuang, X., & Zhang, Z. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01012-1 · Cited by 30
Li, H., Chen, J.-K., Su, Z., Jin, Q., Deng, L., Huang, G., & Shen, J.-N. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02411-y · Cited by 31
Jin, W., Zhang, T., Zhou, W., He, P., Sun, Y., Hu, S., Chen, H., Ma, X., Peng, Y., Yi, Z., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00004 · Cited by 30
Role of extracellular vesicles in osteosarcoma
Yang, Q., Liu, J., Wu, B., Wang, X., Jiang, Y., & Zhu, D. (2022) · International Journal of Medical Sciences · doi:10.7150/ijms.74137 · Cited by 31
Metadata
- Authors
- Mirabello, L., Troisi, R. J., & Savage, S. A.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Savage, Sharon A.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2009-02-05
- Volume
- 115
- Issue
- 7
- Pages
- 1531-1543
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- PMC
- PMC2813207
- OpenAlex
- W1988325237
- Cited by
- 2,199
- References
- 52
- Citations by year
- 2026: 114 · 2025: 138 · 2024: 166 · 2023: 167 · 2022: 161 · 2021: 194 · 2020: 201 · 2019: 162 · 2018: 172 · 2017: 142 · 2016: 151 · 2015: 129 · 2014: 106 · 2013: 72 · 2012: 52
- FWCI
- 33.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (Z01CP010142)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Keywords
- osteosarcoma, incidence, survival rate, age differences, Paget disease, secondary malignancies, elderly patients, disease stage, SEER, bone tumors, mortality trends
- MeSH terms
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Bone Neoplasms, Child, Child, Preschool, Ethnicity, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Osteosarcoma, Sex Factors, Survival Rate, SEER Program
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
